Abelson murine leukemia virus (A-MuLV) is a replicationdefective transforming retrovirus, which was isolated from a tumor induced in a prednisolone-treated BALB/c mouse inoculated with the nondefective Moloney MuLV (1; for a review, see reference 38). Because of its defectiveness, A-MuLV requires a helper nondefective MuLV to replicate in vivo and in vitro (43) . Its viral genome harbors an oncogene, designated v-abl, apparently derived by recombination between the parental Moloney MuLV genome and the cellular proto-oncogene, c-abl (19, 20) . The v-abl sequences have been shown to be responsible for the transforming potential of this virus (36) . In vivo, when inoculated intraperitoneally, A-MuLV primarily induces nonthymic lymphomas, most frequently of the pre-B-cell phenotype (1, 3, 4, 48), after a short latent period (20 to 40 days). In vitro, A-MuLV can efficiently transform fibroblasts (43) , pre-B lymphocytes (40) , and, under special culture conditions, cells of other hematopoietic lineages (52) .
Two previous studies have shown that the type of helper MuLV used to rescue and replicate A-MuLV profoundly affects the incidence of lymphoma induced by A-MuLV as well as its ability to transform pre-B lymphoid cells in vitro (39, 42) . Indeed, whereas the Moloney MuLV was found to be an efficient helper for A-MuLV to induce lymphomas in vivo and to transform pre-B lymphoid cells in vitro, the A-MuLV rescued with the endogenous BALB/c N-tropic MuLV was found to have no oncogenic potential in vivo and no transforming potential for pre-B lymphoid cells in vitro.
However, A-MuLV rescued with Moloney or N-tropic MuLV could transform fibroblasts in vitro very efficiently, indicating that transformation of fibroblasts and of primary pre-B lymphocytes in vitro had different requirements.
To analyze the role of the helper virus in A-MuLVinduced disease, we tested the oncogenic potential of AMuLV stocks prepared with two different chimeric helper viruses. Previous work in our laboratory and in other laboratories has shown that it is possible to map several determinants on the viral genome by constructing chimeric viruses from the genomes of parental viruses with distinct biological properties. The Fv-J host range determinant (13) and the determinants of thymotropism (16) , of leukemogenicity (15, 17, 25, 31, 35) , of disease specificity (7, 14) , and of paralysis (12) have been mapped by this experimental approach.
We used a similar approach to map the determinant of Moloney MuLV that is responsible for its high lymphogenic potential when complexed with A-MuLV. We constructed chimeric helper viruses with the genomes of parental Moloney and endogenous BALB/c N-tropic MuLVs and used them to rescue and pseudotype A-MuLV. Our results
show that a strong determinant of lymphogenic potential is present at the 3' end of the helper Moloney MuLV genome, involving the 3' end of env and the U3 long terminal repeat (LTR) region. Interestingly, these viral sequences have also been implicated in the leukemogenic potential and the disease specificity (T-cell leukemia, thymoma) of this virus, when inoculated alone (7, 14) . (22) with 32P-labeled purified homologous viral DNA fragments. Positive clones were isolated and grown in mass culture. Plasmid DNA was extracted and molecularly analyzed with appropriate restriction endonucleases by using agarose gels as described previously (13) .
By analysis of the sequence of both Moloney (46) (20 ,ug) were excised from pBR322 by restriction endonuclease digestion, phenol and chloroform extracted, ethanol precipitated, and ligated with T4 DNA ligase (50 U) in 0.5 ml of the ligase buffer. The ligated chimeric viral genomes were then phenol extracted and ethanol precipitated. p7M1 DNA was microinjected as described elsewhere (15) , and p7M2 DNA was transfected on NIH 3T3 cells as previously described (21) . Infectious viruses were detected by reverse transcriptase activity in the medium of transfected cells, as previously described (13) .
Preparation of unintegrated viral DNA. NIH 3T3 cells (8 x 106 cells) were cocultivated with chronically infected cells (4 x 106 cells) in the presence of 2 ,ug of Polybrene per ml. Hirt supernatant DNA was extracted after 48 h of cocultivation as previously described (14) . Restriction analysis of unintegrated viral DNA was done by the procedure of Southern (49), with 32P-labeled representative cloned viral DNA probes.
Preparation of genomic tumor DNAs. Tumor tissues were homogenized in 10 mM Tris, pH 7.5-0.1 M NaCI-10 mM EDTA with a Dounce homogenizer. The homogenized tissues were filtered on several layers of cheesecloth, and sodium dodecyl sulfate (final concentration, 0.5%) was added to this suspension. The lysates were treated overnight with 100 ,ug of pronase (Boehringer Mannheim) per ml at 37°C, and DNA was extracted twice with phenol and once with phenol-chloroform-isoamyl alcohol. DNA was precipitated with ethanol, and the high-molecular-weight DNA was spooled on a glass rod. The DNA was finally suspended in water at 4°C. For digestion, 20 ,ug of DNA was used with appropriate restriction endonucleases under the conditions recommended by the suppliers. DNA fragments were separated on an agarose gel and transferred onto a nitrocellulose membrane by the technique of Southern (49) .
Probes. Virus-specific DNA was detected by hybridization with 32P-labeled gp7O-specific DNA encompassing the env domain of endogenous ecotropic MuLV (24) or with a 32P-labeled U3 LTR DNA fragment specific for the LTR of Moloney MuLV (pLTR-3) (34) . The JH region was analyzed with a 32P-labeled 6.2-kbp germ line JH DNA fragment (2, 41). The murine 1 T-cell receptor gene was analyzed with a 32P-labeled 700-bp RBL5 DNA fragment containing most of the murine C region and 3' untranslated sequence of Cp1 (6) .
Probes were labeled by nick translation (37) or by the random primer extension method with hexamers (Pharmacia P-L Biochemicals, Montreal, Quebec, Canada) (18) .
RESULTS

Construction and characterization of chimeric helper
MuLV genomes. The biological characteristics of the two parental viruses used in this study have been reported previously (39, 42) . Briefly, the helper Moloney MuLV in a complex with the defective A-MuLV induced a lymphoma of pre-B-cell origin after a short latent period (20 to 40 days) in nearly 100% of the inoculated mice. However (24) that distinguishes N-CI-35 (pN20-7) MuLV genome from the Moloney genome. A U3 LTR Moloney-specific probe, which did not hybridize to the N-CI-35 MuLV genome (34) was also used. Results of this analysis revealed that the p7M1 and p7M2 helper viral genomes had the expected structure (data not shown).
Oncogenic potential of A-MuLV pseudotyped with parental and chimeric helper MuLVs. The A-MuLV-transformed nonproducer fibroblast cell line ANN-1 (43) was infected with parental and chimeric MuLVs to prepare virus stocks. The A-MuLV pseudotypes were recovered in the supernatant, and titers were determined for focus formation by infecting rat-1 cells. With Moloney, p7M1, and p7M2 helper MuLVs, it was possible to produce virus stocks having a titer of 2 x 104 FFU/ml, whereas the highest titer obtained with pN20-7 helper MuLV was 0.5 x 104 FFU/ml. An equal amount of FFU of A-MuLV pseudotypes was injected into newborn mice of three strains (NIH Swiss, CD-1, and SWR/J) ( (Fig. 3A) . The Moloney U3 LTR-specific probe detected the same 8.2-kbp XbaI and 4.9-kbp SacI helper fragments in addition to the 5.6-kbp XbaI and 2.6-kbp SacI fragments derived from the defective A-MuLV proviruses (Fig. 3B) (Fig. 3C) PstI-HindIII helper fragment in the same tumors. In addition, XbaI (5.6 kbp) and SacI (2.6 kbp) fragments from the defective A-MuLV proviruses were also detected (Fig. 3D) . Additional fainter bands, most likely representing junction fragments, were also detected in most tumors with this probe (Fig. 3D) . In two tumors (tumors 189 and 192), the expected helper fragments were not detected with gp7O-specific (Fig.  3C, lanes 4 and 6) or U3 LTR-specific (Fig. 3D, lanes 4 and  6) probes, indicating that the helper proviruses had a structure different from that of the inoculated MuLV. The structure of these rearranged proviruses was not studied further. These results indicated that the p7M2 proviruses could be found in tumor DNAs and had the expected structure in several tumors. The presence of Moloney U3 LTR with the novel PstI site was documented by hybridization and by the ability to generate an 8.2-kbp fragment with PstI. The presence of gp7O-specific sequences between the LTRs was documented by hybridization, by the presence of a Sacl site at position 3.7 and XbaI site at position 7. In germ line DNA, the JH region of the immunoglobulin ,u gene is located within a 6.2-kbp EcoRI restriction fragment (6, 41) . In lymphoid cells of B-cell origin (41) , in some T lymphoid cells (10, 28) , and in A-MuLV (Moloney) MuLVtransformed pre-B-lymphoid cell lines established in vitro (3), recombination of a diversity (DH) region to one of the four JH elements could usually be detected on both alleles, leading to the disappearance of the EcoRI germ line fragment and the appearance of two (or more) novel JH-specific EcoRI fragments. Most of the A-MuLV (p7M1) or A-MuLV (p7M2) MuLV-induced primary tumor DNAs (13 of 13 analyzed) had one or more JH-specific novel EcoRI fragments, as the tumors induced with the parental A-MuLV (Moloney) MuLV (Fig. 4) , a result compatible with their B-cell origin. Each tumor had a specific set of EcoRI fragments of relatively equal intensity, suggesting these tumors were clonal or oligoclonal. However, in contrast to what has been usually observed in A-MuLV-transformed cell lines established in vitro (3), the germ line JH 6.2-kbp EcoRI fragment could still be detected in each of our primary tumors analyzed and was sometimes overrepresented, suggesting the presence of cells with unrearranged JH region in these primary B-cell tumors.
To confirm the B-cell-type nature of these A-MuLVtransformed maligant cells, tumor DNAs were hybridized with the P T-cell receptor probe. Rearrangement of the I T-cell receptor sequences has been shown to be an excellent marker for murine lymphoid cells of T-cell origin (23, 27) .
None of the tumor DNAs analyzed showed ,B T-cell receptor rearrangement, indicating that these malignant cells were probably not of T-cell origin (Fig. 5) . Taken together, these results indicate that the target cells transformed by the A-MuLV pseudotyped with the chimeric MuLVs are probably of the same nature (B-cell lineage) as the one transformed by the parental A-MuLV (Moloney) MuLV.
Lack of correlation between the leukemogenic potential of a nondefective MuLV and its ability to be a lymphogenic helper for A-MuLV. The Moloney and BALB/c endogenous Ntropic (N-Cl-35) helper MuLVs used in this study have previously been reported to be highly leukemogenic and nonleukemogenic, respectively, when inoculated alone into newborn mice (26 (Moloney, Friend-N) were also leukemogenic when inoculated alone (39, 42) . Moreover, the other helper MuLVs previously shown to be nononcogenic as A-MuLV pseudotypes (Gross, Kirsten, N-CI-35) were also nonleukemogenic when inoculated alone into newborn mice (26, 39, 42 (29, 32) and to be responsible for the tissue tropism (thymotropism) (16) , leukemogenicity (15, 17, 25, 31) , and disease specificity (7, 14) Our data not only establish a role for these env sequences in the oncogenic process, but they also unravel their role in overcoming the restriction to the Abelson disease seen in CD-1 mice inoculated with A-MuLV (p7M2) (Fig. 2) 24 25 tively, the env portion of the Moloney genome might harbor a second sequence which enhances virus replication. Other regions of Moloney MuLV might also harbor sequences involved in the helper activity for A-MuLV. However, from our present results, these would appear to be not essential. The construction of additional chimeric MuLVs will be needed to study them. Clearly, our results confirm earlier reports on the essential role of the helper virus in oncogenesis by A-MuLV (39, 42) and extend them significantly by identifying one important region of the helper Moloney viral genome involved in this process.
Analysis of primary tumors induced by A-MuLV chimeric helper pseudotypes. The tumors which arose after inoculation of chimeric MuLVs were indistinguishable from the one induced by the wild-type A-MuLV (Moloney) MuLV, both pathologically and with specific markers (JH and ,3-chain T-cell receptor probes): they appear to be of the B-cell lineage. They also appear to be clonal or oligoclonal, when analyzed by the v-abl-specific probe (data not shown) and the JH immunoglobulin probe, suggesting that v-abl is not sufficient to fully transform these cells and that at least one other genetic event (second hit) is required with v-abl (first hit) to transform the pre-B lymphoid cells in vivo. However, in contrast to the rearrangement of both alleles of the JH region which has previously been observed in pre-B lymphoid cells established in vitro, we detected a germ line JH fragment in each primary tumor analyzed, suggesting that the tumor mass was infiltrated, in a significant proportion, by a different cell population, harboring no JH rearrangement and possibly not malignant or by malignant cells of pre-B lineage with a single JH allele rearranged. Establishment of A-MuLV-transformed cells in vitro might eliminate one of these cell populations.
When we analyzed the structure of the proviruses in the induced tumors, we found that the helper proviruses were not rearranged in most A-MuLV (p7M1) MuLV-induced tumors. However, in a significant proportion of the tumors induced by A-MuLV (p7M2) MuLV, the proviruses had rearranged. Either the 3' env Moloney sequences have a protective effect against such rearrangements, or, when it happens in cells containing these sequences, the cells are rejected or acquire a growth disadvantage. Rearrangement of the viral helper genome might be necessary for the lymphogenic potential of A-MuLV (p7M2) MuLV but does not appear to be so, since many tumors had a nonrearranged helper p7M2 MuLV genome. However, small changes would have remained undetected by the restriction enzyme analysis performed. The molecular nature of this phenomenon remains obscure.
How does the helper MuLV promote oncogenicity by AMuLV? The mechanism by which the helper virus participates in the oncogenic transformation by A-MuLV could be extracellular or intracellular (39) . Our data indicate that the LTR, which is a noncoding region and which is absent in the extracellular part of the virus cycle, is involved in this process, strongly suggesting an intracellular role for the helper virus. In fact, Rosenberg and Baltimore (39) (16) . The LTRs of only a few murine retroviruses seem to be able to function in pre-B target lymphoid cells. And, as indicated by our results with Gross passage A MuLV, this property is independent of the leukemogenic potential of the virus used. So, the LTR of some MuLVs, such as Moloney, seem to be effective in T and pre-B lymphoid cells, whereas the LTRs of others (such as Gross passage A MuLV) appear to be effective only in T lymphoid cells (16, 17) . The intriguing question is why does the A-MuLV (Moloney) MuLV, when inoculated intraperitoneally, almost never give rise to acute T cell lymphoma and do so only when inoculated intrathymically (9, 44) ?
The tumors which eventually appeared were not polyclonal but arose from a single cell or from very few infected cells; they were clonal or oligoclonal. An (11, 30, 45, 50, 51) ; this is the same mechanism, we suggest, by which it might operate to transform pre-B lymphoid cells in collaboration with v-abl.
